BioSpace News Archive

Technavio has announced its latest market research report titled global digit joint implants market 2019-2023

Amarin Corporation plc announced that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2020 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.

Lianluo Smart Limited announced that it has received a letter from the staff of The Nasdaq Stock Market LLC on January 2, 2020, providing notification that the Company no longer complies with the minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market under Nasdaq’s Listing Rule 5550 and that the Company also does not comply with either of the two alternative standards of Listing Rule 5550, the market value standard and the net income standard.

SpringWorks Therapeutics, Inc. announced that Saqib Islam, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020 at 1:30 p.m. Pacific Standard Time.

LabCorp® announced that members of the executive management team will participate in a fireside chat at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14 at 1:30 p.m..

MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the U.S. Biomedical Advanced Research and Development Authority within the Assistant Secretary for Preparedness and Response, a part of the U.S. Department of Health and Human Services, has begun procuring NexoBrid® for emergency stockpile as part of the HHS mission to build national preparedness for public health medical emergencies.

Merck announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.

PLx Pharma Inc., a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg, announced that the U.S. Food and Drug Administration is providing clarification for the regulatory path forward for VAZALORE.

Allergan plc, announced that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island.

Technavio has announced its latest market research report titled global amniotic membrane market 2020-2024